AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Beats Revenue Estimates
ABCELLERA BIOLG (ABCL) delivered earnings and revenue surprises of +29.41% and +146.95%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?